The Pacific Journal of Oncology & Immunotherapy (PJOI) is unwaveringly committed to the principles of open access, ensuring that all published research is freely accessible to the global community without any financial, legal, or technical barriers. By embracing the philosophy that knowledge should be universally available, PJOI promotes unrestricted information sharing, accelerating advancements in cancer treatment and immunotherapy worldwide.

 

Creative Commons Attribution-NonCommercial (CC BY-NC) License

All articles published in PJOI are licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) license. This licensing framework allows users to freely access, download, share, and redistribute the work in any medium or format, provided the following conditions are met:

• Attribution: Users must give appropriate credit to the original authors and the journal, provide a link to the license, and indicate if any changes were made. Attribution should not imply endorsement by the authors or PJOI.
• NonCommercial: The work may not be used for commercial purposes. Users are free to copy, distribute, and display the content and create derivative works based on it, provided such use is not intended for commercial gain.

Key Aspects of Our Open Access Policy

1. Free Access to Content

All research articles, reviews, case studies, and other content published in PJOI are freely accessible to anyone with an internet connection. There are no subscription fees, registration requirements, or paywalls restricting access to the journal's content.

2. Immediate Availability

Articles are made available immediately upon publication, ensuring that new research is rapidly disseminated to the global audience. This prompt access supports the timely exchange of ideas and knowledge within the oncology and immunotherapy communities.

3. Rights Retained by Authors

Authors retain the copyright of their work while granting PJOI the right to publish it under the CC BY-NC license. This arrangement allows authors to maintain control over their intellectual property while ensuring their work reaches a broad and diverse audience.

4. Permissible Use by Readers

Readers are encouraged to read, download, print, and share articles published in PJOI. They may also adapt or remix the content, provided it is not for commercial purposes and appropriate credit is given to the original authors and the journal.
Educational institutions, researchers, and practitioners can freely use the content for teaching, research, and non-commercial purposes, enhancing the dissemination and impact of the research.

5. Restrictions on Commercial Use

While the CC BY-NC license allows for broad dissemination and use of the content, any commercial use of the material—such as selling, redistributing for commercial purposes, or using the content in a product or service that generates profit—is not permitted without obtaining additional permissions from the copyright holders.

6. Enhancing Research Impact

By adopting an open-access model under the CC BY-NC license, PJOI enhances the visibility and impact of the research it publishes. Open-access articles are more likely to be cited, discussed, and built upon, driving further innovation and advancement in oncology and immunotherapy.

7. Compliance with Funding Requirements

Many research funding agencies now mandate that the results of the research they support be published in open-access journals. By publishing in PJOI, authors can comply with these requirements, ensuring that their work meets the open-access mandates of their funders.

8. Global Reach

PJOI’s open-access policy ensures that the research is accessible to scholars and practitioners in both well-resourced institutions and those in low- and middle-income countries, contributing to a more equitable global research environment.